bioRxiv ScienceSearch

Biology subjects

Hankinson, T. C.

Publications and source records attributed to Hankinson, T. C..

2 recordsLinked to original sources

Linnaeus: Interpretable Deep Learning Classification of Single Cell Transcript Data

High throughput data is commonplace in biomedical research as seen with technologies such as single-cell RNA sequencing (scRNA-seq) and other Next Generation Sequencing technologies. As these techniques continue to be increasingly utilized it is critical to have analysis tools that can identify meaningful complex relationships between variables (i.e., in the case of scRNA-seq: genes) in a way such that human bias is absent. Moreover, it is equally paramount that both linear and non-linear (i.e., one-to-many) variable relationships be considered when contrasting datasets. HD Spot is a deep learning-based framework that generates an optimal interpretable classifier a given high-throughput dataset using a simple genetic algorithm as well as an autoencoder to classifier transfer learning approach. Using four unique publicly available scRNA-seq datasets with published ground truth, we demonstrate the robustness of HD Spot and the ability to identify ontologically accurate gene lists for a given data subset. HD Spot serves as a bioinformatic tool to allow novice and advanced analysts to gain complex insight into their respective datasets enabling novel hypotheses development.

bioinformatics

Comprehensive molecular characterization of pediatric treatment-induced high-grade glioma: A distinct entity despite disparate etiologies with defining molecular characteristics and potential therapeutic targets

Treatment-induced high-grade gliomas (TIHGGs) are an incurable late complication of cranial radiation therapy or combined radiation/chemotherapy used to treat pediatric cancer. We assembled a cohort of 33 TIHGGs from multiple institutions. The primary antecedent malignancies were medulloblastoma, acute lymphoblastic leukemia, astrocytoma, and ependymoma. We performed methylation profiling, RNA-seq, and genomic sequencing (whole-genome or whole-exome) on TIHGG samples. Methylation profiling revealed that TIHGGs cluster primarily with the pediatric receptor tyrosine kinase I subtype (26/31 samples). Common TIHGG copy-number alterations include Chromosome (Ch.) 1p loss/1q gain, Ch. 4 loss, Ch. 6q loss, and Ch. 13 and Ch. 14 loss; focal alterations include PDGFRA and CDK4 gain and loss of CDKN2A and BCOR. Relative to de novo pediatric high-grade glioma (pHGG), BCOR loss (p=0.004) and CDKN2A loss (p=0.005) were significantly increased. Transcriptomic analysis identified two distinct TIHGG subgroups, one with a lesser mutation burden (0.12 mut/Mb), Ch. 1p loss/1q gain (5/6 samples), and stem cell characteristics, and one with a greater mutation burden (1.08 mut/Mb, p<0.0002), depletion of DNA repair pathways, and inflammatory characteristics. We observed increased chromothripsis in TIHGG versus pHGG (67% vs. 31%, p=0.036), which was associated with extrachromosomal circular DNA-mediated amplification of PDGFRA and CDK4. In vitro drug screening in one primary, patient-derived TIHGG cell line from each expression subgroup identified microtubule inhibitors/stabilizers, DNA-damaging agents, MEK inhibition, and, in the inflammatory subgroup, proteasome inhibitors as potentially effective therapies. This study provides a comprehensive molecular profile of TIHGG, including mechanistic insights to TIHGG oncogenesis, and identifies potentially effective therapeutic modalities for further investigation.

cancer biology